287 related articles for article (PubMed ID: 28531845)
1. Artesunate and erythropoietin synergistically improve the outcome of experimental cerebral malaria.
Du Y; Chen G; Zhang X; Yu C; Cao Y; Cui L
Int Immunopharmacol; 2017 Jul; 48():219-230. PubMed ID: 28531845
[TBL] [Abstract][Full Text] [Related]
2. Artesunate-erythropoietin combination for murine cerebral malaria treatment.
Bienvenu AL; Ferrandiz J; Kaiser K; Latour C; Picot S
Acta Trop; 2008 May; 106(2):104-8. PubMed ID: 18359468
[TBL] [Abstract][Full Text] [Related]
3. S1P is associated with protection in human and experimental cerebral malaria.
Finney CA; Hawkes CA; Kain DC; Dhabangi A; Musoke C; Cserti-Gazdewich C; Oravecz T; Liles WC; Kain KC
Mol Med; 2011; 17(7-8):717-25. PubMed ID: 21556483
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin protects against murine cerebral malaria through actions on host cellular immunity.
Wei X; Li Y; Sun X; Zhu X; Feng Y; Liu J; Jiang Y; Shang H; Cui L; Cao Y
Infect Immun; 2014 Jan; 82(1):165-73. PubMed ID: 24126529
[TBL] [Abstract][Full Text] [Related]
5. RNA-seq-based transcriptome analysis of the anti-inflammatory effect of artesunate in the early treatment of the mouse cerebral malaria model.
Wang Q; Tang Y; Pan Z; Yuan Y; Zou Y; Zhang H; Guo X; Guo W; Huang X; Wu Z; Li C; Xu Q; Song J; Deng C
Mol Omics; 2022 Sep; 18(8):716-730. PubMed ID: 35960011
[TBL] [Abstract][Full Text] [Related]
6. Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain.
Clemmer L; Martins YC; Zanini GM; Frangos JA; Carvalho LJ
Antimicrob Agents Chemother; 2011 Apr; 55(4):1383-90. PubMed ID: 21220531
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of artesunate combined with Atractylodes lancea or Prabchompoothaweep remedy extracts as adjunctive therapy for the treatment of cerebral malaria.
Plirat W; Chaniad P; Phuwajaroanpong A; Konyanee A; Viriyavejakul P; Septama AW; Punsawad C
BMC Complement Med Ther; 2023 Sep; 23(1):332. PubMed ID: 37730604
[TBL] [Abstract][Full Text] [Related]
8. Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria.
Miranda AS; Brant F; Rocha NP; Cisalpino D; Rodrigues DH; Souza DG; Machado FS; Rachid MA; Teixeira AL; Campos AC
Malar J; 2013 Nov; 12():388. PubMed ID: 24180288
[TBL] [Abstract][Full Text] [Related]
9. Phenylhydrazine administration accelerates the development of experimental cerebral malaria.
Zhu X; Liu J; Feng Y; Pang W; Qi Z; Jiang Y; Shang H; Cao Y
Exp Parasitol; 2015 Sep; 156():1-11. PubMed ID: 26005191
[TBL] [Abstract][Full Text] [Related]
10.
Elphinstone RE; Besla R; Shikatani EA; Lu Z; Hausladen A; Davies M; Robbins CS; Husain M; Stamler JS; Kain KC
Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28674030
[TBL] [Abstract][Full Text] [Related]
11. Beta interferon suppresses the development of experimental cerebral malaria.
Morrell CN; Srivastava K; Swaim A; Lee MT; Chen J; Nagineni C; Hooks JJ; Detrick B
Infect Immun; 2011 Apr; 79(4):1750-8. PubMed ID: 21245265
[TBL] [Abstract][Full Text] [Related]
12. Suppressor of cytokine signaling 2 modulates the immune response profile and development of experimental cerebral malaria.
Brant F; Miranda AS; Esper L; Gualdrón-López M; Cisalpino D; de Souza DDG; Rachid MA; Tanowitz HB; Teixeira MM; Teixeira AL; Machado FS
Brain Behav Immun; 2016 May; 54():73-85. PubMed ID: 26765997
[TBL] [Abstract][Full Text] [Related]
13. [Protective effects of artesunate combination on experimental cerebral malaria and nerve injury].
Jiang XH; Chen LN; Li K; Guo Y; Zheng ZY; Yang T; Zheng XJ; Li YJ; Zhu XX
Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3051-3057. PubMed ID: 30200698
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria.
Campos AC; Brant F; Miranda AS; Machado FS; Teixeira AL
Neuroscience; 2015 Mar; 289():166-80. PubMed ID: 25595981
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin-1 attenuates mortality associated with experimental cerebral malaria.
Solomon W; Wilson NO; Anderson L; Pitts S; Patrickson J; Liu M; Ford BD; Stiles JK
J Neuroinflammation; 2014 Jan; 11():9. PubMed ID: 24433482
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.
Wilson NO; Solomon W; Anderson L; Patrickson J; Pitts S; Bond V; Liu M; Stiles JK
PLoS One; 2013; 8(4):e60898. PubMed ID: 23630573
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.
Odhiambo OC; Wamakima HN; Magoma GN; Kirira PG; Malala BJ; Kimani FT; Muregi FW
Malar J; 2017 Jul; 16(1):268. PubMed ID: 28673299
[TBL] [Abstract][Full Text] [Related]
18. Oral artesunate prevents Plasmodium berghei Anka infection in mice.
Gumede B; Folb P; Ryffel B
Parasitol Int; 2003 Mar; 52(1):53-9. PubMed ID: 12543147
[TBL] [Abstract][Full Text] [Related]
19. Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA.
Palomo J; Fauconnier M; Coquard L; Gilles M; Meme S; Szeremeta F; Fick L; Franetich JF; Jacobs M; Togbe D; Beloeil JC; Mazier D; Ryffel B; Quesniaux VF
Eur J Immunol; 2013 Oct; 43(10):2683-95. PubMed ID: 23780878
[TBL] [Abstract][Full Text] [Related]
20. Critical role of IL-33 receptor ST2 in experimental cerebral malaria development.
Palomo J; Reverchon F; Piotet J; Besnard AG; Couturier-Maillard A; Maillet I; Tefit M; Erard F; Mazier D; Ryffel B; Quesniaux VF
Eur J Immunol; 2015 May; 45(5):1354-65. PubMed ID: 25682948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
